{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-019249","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.539861+00:00","generated_at":"2026-06-05T04:50:16.804063+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jasper Therapeutics reports FY2023 net loss of $64.5M; cash runway through Q3 2025 on $50M Feb 2024 offering","bullets":["Net loss for FY2023: $64.5M ($6.18 diluted EPS); Q4 net loss $16.6M ($1.50 diluted EPS).","Cash and equivalents $86.9M at Dec 31, 2023; Feb 2024 $50M offering extends runway through Q3 2025.","BEACON Phase 1b/2a in CSU enrolling; initial data from first four cohorts expected Q3 2024.","SPOTLIGHT Phase 1b/2a in CIndU approved; data expected H2 2024.","Phase 1 trial in LR-MDS initiated; initial data anticipated mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-019249","json":"https://secwatch.observer/filing/0001213900-24-019249.json","markdown":"https://secwatch.observer/filing/0001213900-24-019249.md","text":"https://secwatch.observer/filing/0001213900-24-019249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/0001213900-24-019249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/ea0201079-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:50:16.804063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abcd0ef190cce914329b43e25bdfc8ce671b5e84","claim":"Jasper Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: net income $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18, EPS $6.18.","evidence_excerpt":"Jasper reported a net loss of $16.6 million and $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $1.50 and $6.18, for the three months and the year ended December 31, 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390024019249/0001213900-24-019249-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Net income","value":"$64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18"},{"label":"EPS","value":"$6.18"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}